Basic HTML Version
249
Β. Κατσαρός και συν. Ο ρόλος των προηγμένων μεθόδων MRI ΣΕ ΟΓΚΟΥΣ εγκεφάλου
92. JenkinsonMD, Smith TS, Joyce K, et al. MRS of oligo-
dendroglial tumors: correlation with histopathology and
genetic subtypes. Neurology 2005;64(12):2085–9.
93. White ML, Zhang Y, Kirby P, et al. Can tumor contrast
enhancement be used as a criterion for differentiating
tumor grades of oligodendrogliomas? AJNRAmJ
Neuroradiol 2005;26: 784–90.
94. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor
grading and outcome prediction using dynamic
spin-echo MR susceptibility mapping compared with
conventional contrast enhanced MR: confounding effect
of elevated rCBV of oligodendrogliomoas [sic]. AJNR
Am J Neuroradiol 2004;25:214–21.
95. Xu M, See SJ, Ng WH, et al. Comparison of magnetic
resonance spectroscopy and perfusion-weighted
imaging in presurgical grading of oligodendroglial
tumors. Neurosurgery 2005;56:919–24.
96. Chernov M, Hayashi M, Izawa M, et al. Differentiation
of the radiation-induced necrosis and tumor recurrence
after gamma knife radiosurgery for brain metastases:
importance of multi-voxel proton MRS. Minim Invasive
Neurosurg 2005;48(4):228–34.
97. Gajewicz W, Grzelak P, Gorska-Chrzastek M, et al.
[The usefulness of fused MRI and SPECT images for
the voxel positioning in proton magnetic resonance
spectroscopy and planning the biopsy of brain tumors:
presentation of the method] [abstract]. Neurol Neurochir
Pol 2006;40(4):284–90 [in Polish].
98. Hall WA , Martin A, Liu H, et al. Improving diagnostic
yield in brain biopsy: coupling spectroscopic targeting
with real-time needle placement. JMagn Reson Imaging
2001;13(1):12–5.
99. PayneGS,LeachMO.Applicationsofmagneticresonance
spectroscopy in radiotherapy treatment planning. Br J
Radiol 2006;79(Special Issue 1):S16–26.
100. Graves EE, NelsonSJ, VigneronDB, et al. Apreliminary
study of the prognostic value of 1H-spectroscopy in
gamma knife radiosurgery of recurrent malignant
gliomas. Neurosurgery (Baltimore) 2000;46:319–28.
101. Graves EE, Pirzkall A, Nelson SJ, et al. Registration
of magnetic resonance spectroscopic imaging to
computed tomography for radiotherapy treatment
planning. Med Phys 2001;28: 2489–96.
102. Cohen BA, Knopp EA, Rusinek H, et al. Assessing
global invasion of newly diagnosed glial tumors with
whole-brain proton MR spectroscopy. AJNR Am J
Neuroradiol 2005;26(9): 2170–7.
103. Matulewicz L, Sokol M, Wydmanski J, et al. Could
lipid CH2/CH3 analysis by in vivo 1H MRS help in
differentiation of tumor recurrence and post-radiation
effects? Folia Neuropathol 2006;44(2):116–24.
104. Chan YL, Yeung DK, Leung SF, et al. Proton magnetic
resonance spectroscopy of late delayed radiation-
induced injury of the brain. J Magn Reson Imaging
1999; 10(2):130–7.
105. Graves EE, Nelson SJ, Vigneron DB, et al. Serial proton
MR spectroscopic imaging of recurrent malignant
gliomas after gamma knife radiosurgery. AJNRAmJ
Neuroradiol 2001; 2:613–24.
106. Plotkin M, Eisenacher J, Bruhn H, et al. 123I-IMT
SPECT and 1H MR-spectroscopy at 3.0 T in the dif-
ferential diagnosis of recurrent or residual gliomas: a
comparative study. J Neurooncol 2004;70(1):49–58.
107. Hollingworth W, Medina LS, Lenkinski RE, et al. A
systematic literature review of magnetic resonance
spectroscopy for the characterization of brain tumors
[review]. AJNR Am J Neuroradiol 2006;27(7):1404–
11.
108. Kaur B, Tan C, Brat DJ, et al. Genetic and hypoxic
regulation of angiogenesis in gliomas [review]. J
Neurooncol 2004;70(2):229–43.
109. Manoonkitiwongsa PS, Schultz RL, Whitter EF, et
al. Contraindications of VEGF-based therapeutic
angiogenesis: effects on macrophage density and
histology of normal and ischemic brains. Vascul
Pharmacol 2006;44(5):316–25.
110. Liebner S, FischmannA, RascherG, et al.Claudin-1and
claudin-5 expression and tight junction morphology
are altered in blood vessels of human glioblastoma
multiforme. ActaNeuropathol (Berl) 2000;100(3):323–
31.
111. Davies DC. Blood-brain barrier breakdown in septic
encephalopathy and brain tumours [review]. J Anat
2002;200(6):639–46.
112. Nakagawa T, Tanaka R, Takeuch i S, e t a l .
Haemodynamic evaluation of cerebral gliomas using
XeCT. Acta Neurochir (Wien) 1998;140(3):223–33.
113 Muizelaar JP, Fatouros PP, Schroder ML. A new
method for quantitative regional cerebral blood volume
measurements using computed tomography. Stroke
1997;28(10): 1998–2005.
114. Yang S, Law M, Zagzag D. Dynamic contrast-en-
hanced perfusion MR imaging measurements of en-
dothelial permeability: differentiation between atypical
and typical meningiomas. AJNR Am J Neuroradiol
2003;24:1554–9.
115. Hartmann M, Heiland S, Harting I, et al. Distinguishing
of primary cerebral lymphoma fromhigh-grade gliomas
with perfusion-weighted magnetic resonance imaging.
Neurosci Lett 2003;338:119–22.
116. Rollin N, Guyotat J, Streichenberger N, et al. Clinical
relevance of di ffusion and perfusion magnet ic
resonance imaging in assessing intra-axial brain tumors.
Neuroradiology 2006; 48(3):150–9.
117. Essig M, Waschkies M, Wenz F, et al. Assessment of
brain metastases with dynamic susceptibility- weighted
contrast-enhancedMRimaging: initial results.Radiology
2003;228(1): 193–9.
118. Kremer S, Grand S, Berger F, et al. Dynamic contrast-
enhanced MRI: differentiating melanoma and renal
carcinoma metastases from high-grade astrocytomas and
other metastases. Neuroradiology 2003;45(1):44–9.
119. Kremer S, Grand S,Remy C, et al. Contribution of
dynamic contrastMR imaging to the differentiation